ReviewJournal of hepatology2018
Fructose and sugar: A major mediator of non-alcoholic fatty liver disease.
Review in Journal of hepatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04898621 (The Effect of Dietary Fructose on Gut Microbiota and Hepatosteatosis in Healthy Men), which is not on this map. Cited by 460 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Dietary Fructose on Gut Microbiota and Hepatosteatosis in Healthy Men
Who cites it
460 citing papers in PubMed, 4 syntheses or guidelines pooled it, 897 citations in OpenAlex.
- The impact of high fructose corn syrup on liver injury and glucose metabolism: a systematic review.Frontiers in nutrition · 2025Pooled it
- Low-carbohydrate diets reduce cardiovascular risk factor levels in patients with metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials.Frontiers in nutrition · 2025Pooled it
- Ultra-processed foods and non-alcoholic fatty liver disease: an updated systematic review and dose-response meta-analysis.Frontiers in nutrition · 2025Pooled it
- Ultra-Processed Food Intake Is Associated with Non-Alcoholic Fatty Liver Disease in Adults: A Systematic Review and Meta-Analysis.Nutrients · 2023Pooled it
- NAFLD-related SNPs are linked to changes in liver fat, as measured by the CAP score, and serum lipids in response to a 3-week sugar-sweetened beverage intervention: a pilot study.Food & function · 2026Trial
- Consecutive fecal microbiota transplantation for metabolic dysfunction-associated steatotic liver disease: a randomized controlled trial.Gut microbes · 2025Trial
- Ketogenic diet but not free-sugar restriction alters glucose tolerance, lipid metabolism, peripheral tissue phenotype, and gut microbiome: RCT.Cell reports. Medicine · 2024Trial
- Trial
- Cardiovascular Complications of Chronic Liver Disease.Circulation · 2026Review
- Dietary sodium density as a potential nutritional marker of HSI-defined hepatic steatosis in Korean adults: a nationwide cross-sectional study with a dose-response analysis.Internal and emergency medicine · 2026Article
- Glyoxalase 1 loss reduces fatty liver but impairs glucose handling in male mice.Physiological reports · 2026Article
- Combined Protective Effects of Raffinose and Isoflavones Against High-Fructose-Induced Liver Damage via Improved Bioavailability and Metabolic Regulation.Foods (Basel, Switzerland) · 2026Article
- Intestinal fructose catabolism promotes obesity and insulin resistance via ileal lacteal remodeling.Science advances · 2026Article
- Housing at 27 °C, a Near-Thermoneutral Temperature, Exacerbates Metabolic Dysfunction-Associated Steatohepatitis in C57BL/6J Mice.International journal of molecular sciences · 2026Article
- Multi-modal AI-enabled steatotic liver disease diagnostics using facial images and metabolomics.Cell reports. Medicine · 2026Article
- The MASLD-Cardio-Oncology Triangle: Dietary Patterns, Metabolic Remodelling and Implications for Cancer Therapy Tolerance.Nutrients · 2026Review
- MASLD: Spatial Mechanisms and New Therapeutics.Biomolecules · 2026Review
- Gut Microbiota, Immunity, and Metabolism in the Progression From Chronic Liver Disease to Hepatocellular Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Cross-talk between glycosylation pathways: Mechanistic insights and implications for human diseases.Molecular metabolism · 2026Review
- Dexpanthenol Attenuates High-Fructose Corn Syrup-Induced Hepatic Injury in Young Adult Rats by Modulating Oxidative Stress, Apoptosis, and Inflammasome-Associated Pyroptotic Signaling.International journal of molecular sciences · 2026Article
400 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 4 countries.
Funding
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome; its rising prevalence parallels the rise in obesity and diabetes. Historically thought to result from overnutrition and a sedentary lifestyle, recent evidence suggests that diets high in sugar (from sucrose and/or high-fructose corn syrup [HFCS]) not only increase the risk of NAFLD, but also non-alcoholic steatohepatitis (NASH). Herein, we review the experimental and clinical evidence that fructose precipitates fat accumulation in the liver, due to both increased lipogenesis and impaired fat oxidation. Recent evidence suggests that the predisposition to fatty liver is linked to the metabolism of fructose by fructokinase C, which results in ATP consumption, nucleotide turnover and uric acid generation that mediate fat accumulation. Alterations to gut permeability, the microbiome, and associated endotoxemia contribute to the risk of NAFLD and NASH. Early clinical studies suggest that reducing sugary beverages and total fructose intake, especially from added sugars, may have a significant benefit on reducing hepatic fat accumulation. We suggest larger, more definitive trials to determine if lowering sugar/HFCS intake, and/or blocking uric acid generation, may help reduce NAFLD and its downstream complications of cirrhosis and chronic liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.